No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
CRMD CorMedix
- 4.705
- +0.055+1.18%
Trading Jul 22 11:59 ET
258.58MMarket Cap-5114P/E (TTM)
4.780High4.650Low139.25KVolume4.650Open4.650Pre Close657.11KTurnover0.26%Turnover RatioLossP/E (Static)54.96MShares7.00052wk High4.46P/B256.05MFloat Cap2.57052wk Low--Dividend TTM54.42MShs Float52.000Historical High--Div YieldTTM2.80%Amplitude0.729Historical Low4.718Avg Price1Lot Size
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | CorMedix Inc. Announces Outpatient Availability of Defencath
CorMedix Inc. Announces Outpatient Availability of DefenCath
BERKELEY HEIGHTS, N.J., July 03, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing therapeutic products for life-threatening diseases and conditions, today
CORMEDIX INC. ANNOUNCES OUTPATIENT AVAILABILITY OF DEFENCATH
July 3, 2024Berkeley Heights, NJ – July 3, 2024 – CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing therapeutic products for life-threatening diseases and conditions, tod
Truist Financial Initiates CorMedix(CRMD.US) With Buy Rating
Truist Financial analyst Nicole Germino initiates coverage on $CorMedix(CRMD.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 57.7% and a total average return of 67
Needham Maintains CorMedix(CRMD.US) With Buy Rating, Maintains Target Price $10
Needham analyst Serge Belanger maintains $CorMedix(CRMD.US)$ with a buy rating, and maintains the target price at $10.According to TipRanks data, the analyst has a success rate of 41.9% and a total av
CorMedix to Start DefenCath Label Expansion Program This Year
Comments
$CorMedix(CRMD.US$ CorMedix Announces CMS Grants Pass-Through Status For DefenCath Under Hospital Outpatient Prospective Payment System (OPPS)
$CorMedix(CRMD.US$ CorMedix: TDAPA Program Provides for Five Years Additional Payment Reimbursement >CRMD
Dow Jones· 4 mins ago. CorMedix: DefenCath Catheter Lock Solution Is FDA Approved to Reduce Incidence of Catheter-Related Bloodstream Infections in Adult Patients With Kidney Failure >CRMD
Dow Jones· 2 mins ago
Dow Jones· 4 mins ago. CorMedix: DefenCath Catheter Lock Solution Is FDA Approved to Reduce Incidence of Catheter-Related Bloodstream Infections in Adult Patients With Kidney Failure >CRMD
Dow Jones· 2 mins ago
$CorMedix(CRMD.US$ CorMedix Inc. Announces U.S. Inpatient Commercial Availability of Defencath® (Taurolidine and Heparin)
$CorMedix(CRMD.US$ Two Of CorMedix Abstracts Accepted For Presentation At SHEA Conference
Benzinga· just
Benzinga· just
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg